Multi-kinase inhibitor 4

• UNSPSC Description:

  Multi-kinase inhibitor 4 (compound 14) is an orally active inhibitor of FLT1, KDR, FLT3, FLT4, PDGFRα, PDGFRβ, with IC50s of 1.97 nM, 1.04 nM, 0.33 nM, 1.44 nM, 0.18 nM, 0.89 nM. Multi-kinase inhibitor 4 plays an important role in cancer research[1].

• Target Antigen:

  FLT3; PDGFR

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/multi-kinase-inhibitor-4.html

• Smiles:

  O=C(NC1=CC(C(C)(C)C)=NO1)CC(C=C2)=CC=C2N3C4=CC=C(C5=CNN=C5)C=C4N=C3

• Molecular Weight:

  440.50

• References & Citations:

  [1]Debasis Das, et al. Discovery of novel, orally bioavailable phenylacetamide derivatives as multikinase inhibitors and in vivo efficacy study in hepatocellular carcinoma animal models. Bioorg Med Chem Lett. 2024 Sep 19:113:129971. |[2]Debasis Das, et al. Discovery of novel, orally bioavailable phenylacetamide derivatives as multikinase inhibitors and in vivo efficacy study in hepatocellular carcinoma animal models. Bioorg Med Chem Lett. 2024 Sep 19:113:129971.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2648279-77-8